Eur Rev Med Pharmacol Sci 2023; 27 (8): 3753-3765
DOI: 10.26355/eurrev_202304_32174

Effects of comorbidities associated with COVID-19 cases in Intensive Care Unit on mortality and disease progression

S. Girgin, M. Aksun, A.S. Tüzen, A. Şencan, O. Şanlı, G. Kırbaş, S. Güven, B.E. Gölboyu, N. Karahan

Department of Anesthesiology and Reanimation, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey. astuzen@icloud.com


OBJECTIVE: The patient’s age, gender and the presence of certain concomitant diseases have been reported to play a part in the course and progression of COVID-19 in the literature. In this study, we aimed to compare the comorbidities causing mortality in critically ill Intensive Care Unit (ICU)-patients diagnosed with COVID-19.

PATIENTS AND METHODS: The data as regards the COVID-19 cases followed up in the ICU were retrospectively reviewed. 408 COVID-19 patients with positive PCR test were included in the study. In addition, a subgroup analysis was performed in patients treated with invasive mechanical ventilation. While the primary aim of this study was to evaluate the difference in survival rates due to comorbidities in critical COVID-19 patients, we also aimed to assess the comorbidities in severely intubated COVID-19 patients in terms of mortality.

RESULTS: A statistically significant increase in mortality was observed in patients with underlying hematologic malignancy and chronic renal failure (p=0.027, 0.047). Body mass index value in the mortal group was significantly higher in both the general study group and subgroup analysis (p=0.004, 0.001).

CONCLUSIONS: Advanced age and comorbidities such as chronic renal failure and hematologic malignancy in COVID-19 patients are associated with poor survival prognosis in critically ill COVID-19 patients.

Free PDF Download

To cite this article

S. Girgin, M. Aksun, A.S. Tüzen, A. Şencan, O. Şanlı, G. Kırbaş, S. Güven, B.E. Gölboyu, N. Karahan
Effects of comorbidities associated with COVID-19 cases in Intensive Care Unit on mortality and disease progression

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 8
Pages: 3753-3765
DOI: 10.26355/eurrev_202304_32174